Noninvasive prenatal testing (NIPT) for monogenic diseases by use of PCR-based strategies requires precise quantification of mutant fetal alleles circulating in the maternal plasma. The study describes the development and validation of a novel assay termed circulating single-molecule amplification and resequencing technology (cSMART) for counting single allelic molecules in plasma. Here we demonstrate the suitability of cSMART for NIPT, with Wilson Disease (WD) as proof of concept.
RESULTS:
Four families with WD pedigrees consented to the study. Using Sanger and whole-exome sequencing, we mapped the pathogenic ATP7B mutations in each pedigree and confirmed the proband's original diagnosis of WD. After validation of cSMART with defined plasma models mimicking fetal inheritance of paternal, maternal, or both parental mutant alleles, we retrospectively showed in second pregnancies that the fetal genotypes assigned by invasive testing and NIPT were concordant.
CONCLUSIONS:
We developed a reliable and accurate NIPT assay that correctly diagnosed the fetal genotypes in 4 pregnancies at risk for WD. This novel technology has potential as a universal strategy for NIPT of other monogenic disorders, since it requires only knowledge of the parental pathogenic mutations.
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Diagnosis of monogenic diseases during pregnancy is currently performed by molecular analysis of the fetal cells retrieved by either chorionic villus sampling or amniocentesis (1 ) . In the diagnostic laboratory, the causative mutations established by family DNA studies or analysis of an affected proband are directly targeted by PCR and Sanger sequencing, and if 1 or both mutations are unknown, linkage analysis with short tandem repeats can be used as an alternative strategy (1, 2 ) . These approaches are highly reliable and accurate for defining the genotype of the fetus and, if the fetus is affected, allow the couple to make a decision regarding termination of pregnancy. More recently, with the advent of whole-exome sequencing, pathogenic mutations can be readily identified for almost any monogenic disease, and this approach has proven to be particularly useful to identify novel or rare mutations in families (3 ) and to aid in establishing a more definitive diagnosis of individuals with unclear clinical phenotypes (4, 5 ) .
After the successful implementation of noninvasive prenatal testing (NIPT) 4 for common chromosome disorders (6, 7 ) and promising reports for clinically significant copy number variations (8 -10 ) , one of the obvious extensions to the technology is reliable and accurate testing for monogenic disorders (11 ) . Nonetheless, the presence of low levels of circulating cell-free fetal DNA in the maternal plasma-as low as 25 genome copies/mL between 11 and 17 weeks of gestation (12 ) with an average size of 166 base pairs (13 )-presents a very problematic template for analysis by conventional diagnostic ap-proaches. Nonetheless, the possibility of NIPT for singlegene disease has already been demonstrated with digital PCR to measure the relative mutation dosage (14 ) , enabling the detection of mutations associated with major blood disorders ␤-thalassemia (15 ) , sickle cell anemia (16 ) , and hemophilia (17 ) and the determination of RhD antigen genotypes (18 ) . More recently, relative haplotype dosage analysis of the HBB (hemoglobin, ␤) 5 gene combined with digital PCR was successfully applied to correctly genotype the established fetuses from 2 pregnancies at risk for ␤-thalassemia (19 ) . However, although promising results have been reported, digital PCR remains technically challenging for most molecular diagnostic laboratories (14 ) , and thus this technology has not seen rapid translation into clinical practice. Currently, only NIPT for RhD genotyping by quantitative PCR targeting of exons 5, 7, and 10 of the RHD (Rh blood group, D antigen) gene is clinically available (20 ) , proving highly accurate for determining the presence of an RhD-positive fetus (20, 21 ) .
From first principles and experience gained from molecular diagnostics developed for invasive prenatal diagnosis (1, 2 ), direct allelic targeting remains the most logical strategy for accurately quantitating the randomly fragmented plasma DNA molecules in plasma (13 ) . Conventional PCR with fixed forward and reverse PCR primers bridging multiple mutation loci is 1 feasible approach that is currently being developed. However, with the discovery that maternally derived DNA fragments are on average larger in size than fetally derived fragments (22, 23 ) , the known effects of preferential PCR amplification of smaller over larger fragments could potentially skew the true allelic ratios. Further, this dichotomy of size distribution between maternal and fetal fragments may also promote variable amounts of linear vs exponential amplification in the 2 DNA populations, further skewing allelic ratios. As an alternative approach, we have developed and validated a novel NIPT assay termed circulating single-molecule amplification and resequencing technology (cSMART), in which preamplified single allelic molecules with unique barcodes were targeted and sequenced, but only counted once, eliminating potential PCR size bias and allowing for more precise quantification of the mutant allele percentage in the original plasma sample (Fig. 1) .
As proof of concept, we applied our validated cSMART assay to 4 pregnancies at genetic risk for Wilson disease (WD). WD is a rare inherited autosomal Single allelic molecules (colored lines) were identified by their unique barcodes (colored boxes) and/or unique start/stop sequence. Targeted molecules were sequenced, and unique molecules were counted to determine allelic ratios in the original plasma.
recessive disorder of copper metabolism leading to hepatic damage and neurological disturbances with occasional pathologies of the eyes, kidney, and heart (24, 25 ) . The causal gene is ATP7B (ATPase, Cu ϩϩ transporting, ␤ polypeptide), comprising 21 exons and encoding a copper-transporting protein dependent on the energy stored in ATP (26 ) . Here we show that the fetal genotypes assigned by cSMART analysis of maternal plasma samples were concordant with the original genotypes determined by invasive testing. We propose that cSMART represents a promising new approach for reliable and accurate NIPT of monogenic disorders, since the assay requires only prior knowledge of the parental pathogenic mutations.
Materials and Methods

STUDY DESIGN
The study was approved by the Ethics Committee of the State Key Laboratory of Medical Genetics, Central South University, Hunan, China (approval number 2012S042). Four families with probands exhibiting signs of liver dysfunction consented to participate in the clinical study (Fig. 2 ). Probands were clinically assessed, and pathology tests results led to a provisional diagnosis of WD. Familial pathogenic mutations were identified in ATP7B by Sanger and whole-exome sequencing. All 4 couples conceived a second child and, after amniocentesis, the fetal DNA was genotyped by Sanger sequencing. Retrospectively, we performed NIPT on the frozen maternal plasma with our validated cSMART assay.
SANGER SEQUENCING
Specific primers for amplification of exons 1-21 of ATP7B (26 ) were designed by the Primer3 program (27 ) and used in PCR reactions to generate exonic fragments from the 4 WD pedigrees. Dye terminated sequencing products were electrophoresed on a 3100 Genetic analyzer (Applied Biosystems), and the exon sequences were assembled with DNASTAR Lasergene 7.1 software.
WHOLE-EXOME SEQUENCING
In brief, genomic DNA was fragmented by sonication, and exon-containing fragments were enriched with the SureSelect Target Enrichment kit (Agilent Technologies) according to the manufacturer's standard protocol. Libraries were subjected to paired-end sequencing on the Illumina High Seq 2500 platform. After removing lowquality FASTQ sequencing reads (Phred quality score Ͻ20 from both paired ends), we mapped the remaining high-quality sequences to the human reference genome (hg19) with Burrows-Wheeler Aligner (version 0.7.5a) (28 ) . Data for coverage of the consensus coding sequences by whole-exome sequencing for the WD pedigrees is summarized in Supplemental Table 1 (whole exome) , which accompanies the online version of this article at http://www. clinchem.org/content/vol61/issue1, and online Supplemental Table 2 (WD exons).
DETECTION AND CHARACTERIZATION OF ALLELIC VARIANTS IN ATP7B
We identified single-nucleotide polymorphisms (SNPs) from both Sanger and whole-exome sequencing data with the GATK HaplotypeCaller algorithm (29 ) . All variants were annotated with ANNOVAR (30 ) and searched for matches in dbSNP 138, 1000 Genomes, and ESP6500 databases. Variants of ATP7B, either benign or pathogenic, were identified with SIFT (31 ) and PolyPhen2 (32 ) algorithms to assess effect on ATP7B functional domains. Finally, we compared the pathogenic variants with the Human Gene Mutation Database and the Wilson Disease Mutation Database (33 ) to determine whether they were known or novel mutations.
QUANTIFICATION OF MUTANT ALLELES IN PLASMA BY cSMART
We prepared libraries from 10 ng plasma DNA by ligation of universal sequencing adaptors (6, 34 ) containing unique 6-bp barcodes. Modified molecules were denatured and single strands circularized by Taq ligase. Bidirectional back-to-back primers, in either singleplex or multiplex format, were annealed close to the mutation loci, and inverse PCR was performed to replicate targeted alleles. Amplified products were subjected to massively parallel sequencing on the MiSeq platform (Illumina) to generate paired-end reads of 2 ϫ 200 bp. This strategy was designed to capture all possible allelic fragment sizes to minimize bias but still provide sufficient matching sequence overlap to assemble the targeted alleles. To derive plasma allelic ratios, we counted only uniquely barcoded alleles of different size and map position from the preamplification library. In cases in which the start and stop sequencing bases were identical for 1 or more sequencing reads, we counted only those with a unique barcode. The final allelic ratio was determined from a minimum of 200 uniquely barcoded alleles.
Results
CLINICAL EVALUATION OF PROBANDS
Families G2256, G2671, G2672, and G3203 (Fig. 2) attended different prenatal diagnosis clinics in Hunan and Liaoning provinces with a child who presented with signs of possible liver dysfunction. Each proband was physically examined by the resident physician, and biochemical blood and urinary tests were performed (Table  1 ). All 4 probands had a low circulating concentration of ceruloplasmin, and all probands except G3203 had a high level of excreted copper in the urine. Ultrasound scans for probands G2256 and G2672 revealed liver pa-thologies, including evidence of hepatolenticular degeneration. In ophthalmologic examinations, only proband G2256 displayed evidence of Kayser-Fleischer rings. On the basis of these collective clinical symptoms and abnormal biochemical test results (Table 1) , each proband was given a provisional diagnosis of WD.
IDENTIFICATION OF PATHOGENIC WD MUTATIONS
All 4 families later attended the Hunan Jiahui Genetics Hospital for genetic counseling with a clinical geneticist to discuss their reproductive options. Because all 4 couples were planning for a second pregnancy, they consented to participate in this research study, with the aim of identifying the pathogenic mutations related to the proband's disease symptoms, developing a reliable and accurate invasive prenatal test, and evaluating the performance of our newly developed NIPT cSMART assay.
Sanger sequencing identified potentially pathogenic ATP7B variants in both partners of each couple that had also been inherited by the proband ( Table 1 ). The sequencing profiles of the heterozygous mutations in the 8 parents are shown in Fig. 3 . Six of the DNA variants were missense mutations resulting in single-amino acid substitutions, and 2 DNA variants were frameshift mutations predicted to cause truncation of the mature ATP7B enzyme. Considering the position and nature of the protein changes relative to known ATP7B functional domains, all mutations were predicted to cause either mild or severe impairment of ATP7B enzymatic activity (Table 1).
Whole-exome sequencing also confirmed these 8 pathogenic WD mutations. On this basis, the strong correlation of ATP7B WD genotypes with the corresponding clinical phenotypes of the proband confirmed the provisional diagnosis of WD. Sanger and exome sequencing also identified an additional 4 SNPs in the ATP7B exonic regions of the probands (Table 1) ; however, none of these SNPs caused amino acid substitutions and thus were deemed to be nonpathogenic. Interestingly, by pedigree analysis, SNPs rs9535795 and rs2282057 (G2671), rs1061472 (G2672), and a novel SNP (G3203) could be conclusively linked to either the paternal or maternal WD mutations (Table 1 ; online Supplemental Fig. 1 ).
PRENATAL DIAGNOSIS OF WD FOR AT-RISK FAMILIES
With confirmation of WD genotypes in the probands and the availability of a robust prenatal genotyping test, all 4 couples decided to proceed with a second pregnancy with invasive prenatal diagnosis for WD. After molecular genotyping of amniocyte DNA by Sanger sequencing (Fig. 3) , the established fetuses were found to be heterozygous for p.P992L (G2256), compound heterozygous for p.G1335fs and p.L795F (G2671), homozygous for normal (G2672), and heterozygous for p.S1067N (G3203). Family G2671 elected to terminate the affected pregnancy. The remaining 3 unaffected pregnancies developed to term, resulting in the birth of healthy children without symptoms of WD.
CONCEPT OF cSMART FOR QUANTIFICATION OF MUTANT ALLELE IN MATERNAL PLASMA
The cSMART assay was specifically designed to count the absolute number of unique single allelic molecules in a defined volume of plasma (Fig. 1) . The final method we developed involves circularization of tagged single mater- nal plasma DNA molecules, annealing of back-to-back primers in close vicinity to the mutation loci, inverse PCR, and then massive parallel sequencing of the targeted alleles. By this approach, the percentage of the mutant alleles in the original plasma sample collected from a pregnant woman at risk for a child with a monogenic disease can be quantified, and by applying simple Mendelian inheritance laws, fetal genotypes can be deduced (see online Supplemental Table 3 ). For example, in the case of a pregnancy at risk for an autosomal recessive disease for which both parents carry the same mutation, if the percentage of maternal mutant allele in the plasma is overrepresented (Ͼ50%), underrepresented (Ͻ50%), or remains unchanged (50%), then the fetal genotypes can be inferred as homozygous affected, homozygous normal, or heterozygous normal, respectively. Alternatively, if the paternal mutation is different, the percentage of paternal mutant allele in the maternal plasma can be measured directly. In either mode of inheritance, the percentage deviation from 50% of the mutant maternal allele and/or the percentage of paternal allele would be equivalent to half the fetal DNA fraction.
VALIDATION OF THE cSMART ASSAY FOR FETAL GENOTYPING
Before applying cSMART for NIPT of WD, we performed validation experiments to assess the sensitivity, specificity, and reproducibly of the assay for quantifying predefined levels of mutant alleles in maternal plasma. To mimic fetal inheritance of a paternal WD allele, we seeded a maternal plasma sample with plasma from father G3203 heterozygous for the p.S1067N mutation, to generate 0% (control), 2.5%, 5%, and 7.5% of the final mutant allele. For each final mutant allele percentage, we generated multiple replicates (n ϭ 6 -8) of each sample to assess the accuracy and reproducibility of quantifying the mutant allele. After design of robust targeting primers for mutation p.S1067N, we applied cSMART and compared the actual percentage of mutant alleles detected to the expected values ( Fig. 4 ; online Supplemental Table  4 ). For the 0%, 2.5%, 5%, and 7.5% replicates, the mean (SD) of the experimentally determined mutant allele percentages were 0%, 2.3% (0.62%) (CV ϭ 0.26), 5.59% (0.64%) (CV ϭ 0.11), and 8.53% (1.43%) (CV ϭ 0.16), very similar to theoretical values for each mutant allele percentage. Importantly, the CV for each replicate was small, and there was no overlap in the range of values between 2.5% and 5% replicates or 5% and 7.5% replicates. Further, the control sample yielded no mutant sequencing reads, indicating that the assay was specific. Conversely, to mimic fetal inheritance of a maternal mutant allele, we obtained 11 maternal samples from pregnant women heterozygous for SNP rs1061472, rs2274084, rs72474224, or rs111033313 ( Fig. 4 ; online Supplemental Table 4 ) whose fetuses had inherited the mutant maternal allele and therefore the maternal plasma should have a balance of mutant and wild-type alleles (approximately 50%), regardless of fetal DNA fraction. After cSMART assay, the mean (SD) percentage of mutant alleles in these samples was 50.3% (1.07%) with a CV of 0.02 (Fig. 4) , indicating that cSMART was also highly reliable and accurate for correctly quantifying the inheritance of a mutant maternal allele. Finally, to validate cSMART for detection of a homozygous affected fetus, we analyzed 2 plasma samples for which the fetus was known to inherit 2 copies of the SNP rs72474224 (sample 1) or 2 copies of the SNP rs80338943 (sample 2), and thus the SNP percentage should be approximately 50% plus half the fetal DNA fraction ( Fig. 4 ; online Supplemental Table 4 ). In both samples, the fetal fraction was independently determined by the coanalysis of a maternal heterozygous SNP rs2274084 that was not inherited by the fetus. The expected and actual SNP percentages determined by cSMART were 57.29% (rs2274084) and 55.91% (rs72474224) for sample 1 and 56.32% (rs2274084) and 58.74% (rs80338943) for sample 2, correctly genotyping the 2 fetuses as homozygous affected.
The experimental data derived from these validation studies also allowed us to assess secondary performance parameters of the cSMART assay. In terms of reaction efficiency, on the basis of an average yield of 10 ng DNA/mL plasma (35 ) , which equates to approximately 1500 genome copies, we detected an average of approximately 600 and 300 molecules in 2-and 1-mL plasma samples, respectively (see online Supplemental Table 4 ). This translates to an overall efficiency on the order of 10% for retrieving and counting single plasma DNA molecules in the original plasma samples. This efficiency level was achievable in replicate 2-mL plasma models of a paternally inherited allele even at the lowest fetal DNA fraction of 5%. To assess the effect of the single-molecule barcoding strategy for removing any potential PCR bias associated with the cSMART library preamplification and inverse PCR steps, we examined the size distribution profile of the population of targeted allelic molecules derived from each validation sample. In all samples, the size distribution of the targeted allelic molecules was found to be very similar to that determined for the randomly fragmented plasma DNA molecules, analyzed by either low coverage paired-end sequencing (see online Supplemental Fig. 2) or deeper paired-end sequencing (34 ) . This supports the notion that the unique single-molecule barcoding strategy built into the cSMART assay is effective for removing any significant allelic quantification bias potentially created by the 2 PCR steps in the molecular pipeline.
NIPT OF WD BY cSMART ASSAY
To determine whether our validated cSMART assay could diagnose correct fetal WD genotypes from maternal blood, we retrospectively analyzed the frozen plasma samples from the couples' second pregnancies. For the 8 possible WD mutations, a multiplex primer mixture was designed so that the same cSMART assay could be applied universally to each plasma sample. Preliminary tests on plasma samples without WD mutations showed that the multiplex targeting assay produced a relatively even number of sequencing reads for the 8 wild-type alleles, indicating that multiplexing did not introduce any significant amplification bias toward any particular wildtype allele.
The percentages of mutant plasma WD alleles determined for each pregnancy plasma sample are shown in Table 2 . In pregnancies G2256 and G3203, 4.72% and 5.91% of the mutant paternal allele was detected, balanced by a similar decrease of 5.16% and 9.8% in the percentage of the mutant maternal allele, indicating that the respective fetuses were heterozygous for mutations p.P992L and p.S1067N. In contrast, for pregnancy G2572, no mutant paternal allele was detected, and the percentage of the mutant maternal allele decreased by 7.4%, indicating that the fetus was homozygous normal. In pregnancy G2671, 4.93% of the mutant paternal allele was detected, but the mutant maternal allele remained relatively unchanged at 49.74%, indicating that the fetus was a compound heterozygote for p.G1335fs and p.L795F. Thus, all 4 fetal genotypes assigned by cSMART (Table 2) were concordant with the original genotypes determined by invasive prenatal testing (Fig. 3) . Fetal inheritance of a single mutant paternal allele at 0% (n = 1), 2.5% (n = 8), 5% (n = 6), and 7.5% (n = 6) was modeled with the WD pathogenic mutation p.S1067N, whereas fetal inheritance of a single maternal allele was modeled with SNPs rs1061472, rs2274084, rs72474224, or rs111033313 (n = 11). Observed vs expected SNP percentages are shown by dot plots (median black bar).
Discussion
In this pilot study, we present a new approach for noninvasive diagnosis of monogenetic diseases, with WD as an example of autosomal recessive inheritance. Here, in 4 family pedigrees, Sanger and whole-exome sequencing was successfully applied to identify the 8 pathogenic mutations and confirm the clinical phenotype of the probands as WD. All 8 WD mutations were different, with 4 (p.R778L, p.P992L, p.A874P, p.M769fs) previously reported in Chinese WD patients (36, 37 ) ; four (p.E854G, p.L795F, p.G1335fs, p.S1067N) were not documented in the largest WD mutation database (33 ) and thus deemed novel. In validation studies of the cSMART assay conducted before clinical testing for WD, we first demonstrated that we could correctly and reproducibly quantify the levels of mutant allele in plasma models of fetal paternal and maternal inheritance and additionally in 2 plasma samples for which the respective fetuses were homozygous for 2 different SNPs. Further, we established that the efficiency of cSMART for retrieval of single plasma DNA molecules was on the order of 10% and that correct allelic ratios could be measured in 2-mL plasma volumes at a fetal DNA fraction as low as 5%. In subsequent analyses of the clinical plasma samples from second pregnancies achieved by the 4 couples at genetic risk for a child with WD, we showed that the fetal genotypes diagnosed by traditional invasive prenatal diagnosis were identical to those determined by our validated cSMART assay.
The NIPT diagnoses of WD by cSMART detected 2 cases of paternal allelic inheritance, 1 case of wild-type allelic inheritance, and 1 case of inheritance of both WD alleles, representing 3 of the 4 possible modes of inheritance. In the G303 family case, although the decrease in maternal allele did not precisely match the increase in paternal allele, the correct genotype could still be confidently called. We speculate that a possible bias in the universal target primer mix for the wild-type maternal or WD paternal allele may have been a contributing factor. This observation highlights a possible limitation of the technology when the diagnosis is solely dependent on the 2 paternal mutations. For example, some mutations may be located in neighboring sequences with a high A and T content that are not amenable to robust primer design. One possible solution is to incorporate primers for nonpathogenic SNPs in the assay that can be linked to the pathogenic mutations by pedigree analysis. In this regard, whole-exome sequencing applied in this study proved to be a useful tool not only for identifying the pathogenic WD mutations, but also for detection of linked nonpathogenic SNPs. Thus, the WD cSMART assay we developed could have been designed for even higher reliability and accuracy by the addition of targeting primers for the linked SNPs to the final multiplex mix. Further, the high performance of cSMART demonstrated with a targeting mixture of 8 primers suggests that scaling up to a higher-order multiplex of primers may also be possible to facilitate simultaneous testing of a wider range of mutations in a single assay.
On the basis of the successful application of cSMART to WD, our novel assay should in theory be equally applicable for NIPT of other autosomal recessive, autosomal dominant, and X-linked diseases in which the (38, 39 ) . Identification of the causative DMD mutations by conventional molecular diagnostic methods is complex, although recently, next generation sequencing methodologies have been developed to simplify the analysis (40 ) . In the case of cSMART, deletion mutations would not be amenable to direct and equal targeting of the wild-type and mutant allele. However, if the starting base and/or the ending base of the deletion is known or linked SNPs can be identified, cSMART could also be applied for NIPT of DMD. Nonetheless, further studies on a range of other types of pathogenic mutations and/or linked SNPs associated with common single-gene diseases are still required to determine the overall utility of cSMART for NIPT of monogenic diseases.
In conclusion, proof of concept for a new quantitative allele-targeting method termed cSMART was demonstrated for NIPT of WD. At a minimum, our cSMART assay requires only a knowledge of parental pathogenic mutations or linked SNPs and thus represents a promising laboratory-based methodology for universal NIPT of monogenic diseases. Further, cSMART may have broader applications in the emerging field of early cancer diagnosis for accurately quantitating low levels of tumor-specific circulating DNA in the blood and for monitoring patient response to therapy.
